Fig. 4From: The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational studyPFS in patients with different EGFR-mutant NSCLC subtypes (del19 vs. L858R) treated with 2nd G EGFR-TKIs EGFR, epidermal growth factor receptor; PFS, progression-free survival; TKI, tyrosine kinase inhibitorBack to article page